PubMed Health⌕ Search

Biomedical subjects

A Muner

Publications and source records attributed to A Muner.

2 recordsLinked to original sources

The intestinal ecosystem in chronic functional constipation.

Chronic functional constipation is common in infants, and the bacterial composition of stools in this condition is not known. The study aims were to: (i) investigate the composition of the intestinal ecosystem in chronic functional constipation; (ii) establish whether the addition of the water-holding agent calcium polycarbophil to the diet induces an improvement in constipation; and (iii) determine the composition of the intestinal ecosystem after the use of this agent. In total, 42 children (20F, 22M; mean age: 8.6 +/- 2.9 y) were studied. Twenty-eight children with functional chronic constipation without anatomical disorders were treated double-blind in random sequence for 1 month with an oral preparation of calcium polycarbophil (0.62 g/twice daily) or placebo. Intestinal flora composition was evaluated by standard microbiological methods and biochemical assays on faecal samples collected before and after treatment. Fourteen healthy children were studied as controls. The results show that (i) the constipated children presented a significant increase in clostridia and bifidobacteria in faeces compared to healthy subjects--different species of clostridia and enterobacteriaceae were frequently isolated; no generalized overgrowth was observed; Clostridia outnumbered bacteroides and E. coli mean counts by 2-3log, while bacteroides and E. coli counts were similar (5-6 log10/g fresh faeces); these intestinal disturbances could be defined as a dysbiosis, i.e. a quantitative alteration in the relative proportions of certain intestinal bacterial species. (ii) Clinical resolution of constipation was achieved only in 43% of treated children and an improvement in 21% (one bowel movement every 2 d). (iii) Calcium polycarbophil treatment induced no significant changes in the composition of the intestinal ecosystem, nor in blood chemistry parameters.

Acrylic Resins↗

Pefloxacin penetration into human necrotic pancreatic tissue.

Antibiotic prophylaxis may be useful in acute necrotising pancreatis, a disease associated with a considerable incidence of infectious complications. The aim of this study was to assess pefloxacin penetration into necrotic pancreatic tissue during human necrotic pancreatitis. Ten patients (mean age 53.2 +/- 17.4 years) with severe acute pancreatitis (mean Ranson score 4.3) were studied. Pefloxacin was administered at a dose of 400 mg bd every 12 h by i.v. infusion (bolus, 15 min). Intraoperative samples of necrotic pancreatic tissue and blood were collected simultaneously 1, 2, 4.5, 6, 8.5 or 10 h after the last pefloxacin administration in patients treated for 1, 3, 4, 7, 8, 17 or 20 days. Drug concentrations were determined by the microbiological agar-well diffusion method (Escherichia coli Kp 05124 as test micro-organism in Isosensitest Agar). Levels in serum ranged from 2.0 to 9.0 mg/L (at 2 and 6 h, respectively), in necrotic pancreatic tissue from 2.0 to 29.0 micrograms/g depending on different sampling time. Maximum tissue peak concentrations appeared between 4 and 6 h. The necrotic pancreatic tissue/serum concentration ratio ranged from 0.9 to 5.1, values depending on tissue sample collection. Therapeutic concentrations (20.6 micrograms/g) above the MIC of potentially pathogenic enteric microorganisms were still present in necrotic pancreatic tissue 10 h after the last drug administration. Pefloxacin appeared to concentrate in necrotic pancreatic tissue, without appreciable accumulation after multiple-dose administration. The pefloxacin concentrations in necrotic pancreatic tissue showed high variability, depending on the degree of necrosis, inflammation and sample vascularization. Our results provided evidence of good, prompt penetration of pefloxacin into necrotic pancreatic tissue. Pefloxacin seems to exhibit favourable pharmacokinetic and pharmacodynamic properties for pancreatic infections.

Anti-Infective Agents↗